Clinical Trial Search

Primary: Number of Dose Limiting Toxicities in Patients Taking Atovaquone in Combination With Radical Concurrent Chemoradiotherapy for Non-small Cell Lung Cancer. — 0; 0; 0; 2…

Primary: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUCinf) — 4642; 4980; 4666; 2357 day*μg/mL

Primary: Dose-limiting Toxicities — 0; 0; 0; 0 Participants

Primary: SSA: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1 — 49.6; 52.0; 20.8; 28.0 Percentage of participants

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 2; 5; 5; 33 Participants

Primary: Number of Patients in Which the Treatment Was Tolerable — 5 Participants

Primary: Part A: Maximum Observed Plasma Concentration (Cmax) for Bupropion — 160.5; 201.3; 191.1 Nanogram per milliliter (ng/mL)

Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lebrikizumab — 38.5; 41.9 micrograms per milliliter (µg/mL)

Primary: Period 1: Percent Urinary Recovery (Feurine) of Total Radioactivity — 15.8 percentage of administered dose (%)

Primary: Change From Baseline in QTcF(ΔQTcF) With Placebo Adjustment (ΔΔQTcF) at Cmax of MCI-186 — -0.5; 0.5 ms

Primary: Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 4; 1; 2; 1 Participants

Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0 Participants

Primary: Determination of Maximum Tolerated Dose (MTD) or Highest Tested Dose (HTD). — 2,000,000,000 cells

Primary: The Occurrence of Norovirus-associated Illness in Secretor Positive Participants Through Day 4 After Challenge. — 3; 2; 7; 0 Participants

Primary: Objective Response Rate (Percentage of Patients With Complete Response or Partial Response) — 7.7; 0; 16.7 percentage of participants